In 2022, the global Mucous Membrane Pemphigoid Treatment Market is anticipated to be worth US$ 5.1 billion. It is expected to reach US$ 8.4 billion in 2032 and to grow at a stable CAGR of 5.9% from 2022 to 2032. The market is expected to be fuelled in the near future by the rising demand for immunosuppressants for the treatment of mucous membrane pemphigoid.

Mucous membrane pemphigoid is an uncommon group of chronic autoimmune diseases. These are characterised by blistering lesions that affect an individual's mucosal membranes.

Eyes, mouth, genitalia, nose, anus, and throat mucous membranes are frequently impacted. A blistering and red mouth is frequently the first sign of this illness. The inside of the cheek, the roof of the mouth, and the gums can all be impacted.

It happens when an individual's natural defences against invading or foreign organisms begin destroying healthy tissue for no apparent reason. Throughout the world, ladies are more affected than males by this illness.

Rising awareness campaigns by regulatory agencies to educate the public about the availability of improved treatment options are projected to bode well for the growth of the mucous membrane pemphigoid treatment market. Another reason that is projected to boost the market is the growing demand for higher-quality healthcare products, particularly in developing countries.

Patients' growing demand for oral treatments is forcing various pharmaceutical corporations to produce new therapies. The growing global elderly population is also expected to benefit the global industry.

By Drug Class:

  • Anti-inflammatory Drugs
  • Corticosteroids
  • Monoclonal Antibodies
  • Antibiotics

By Route of Administration:

  • Topical
  • Injectable
  • Oral

By Distribution Channel:

  • Online Pharmacies
  • Drug Stores
  • Retail Pharmacies
  • Hospital Pharmacies

Read More@

Key players covered in the report include:

  • Genentech, Inc.,
  • EPI Health, LLC.,
  • Pfizer Inc.,
  • Astellas Pharma US, Inc.,
  • Actavis Plc.,
  • Lipidor AB,
  • SUN PHARMA company,
  • Merck Sharp & Dohme,
  • GlaxoSmithKline plc.,
  • Bausch Health